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Abstract. Glioma is an aggressive central nervous system 
malignancy. MicroRNAs (miRNAs/miRs) have been reported 
to be involved in the tumorigenesis of numerous types of 
cancer, including glioma. The present study aimed to identify 
the differentially expressed miRNAs in glioma, and further 
explore the clinical value of miR-455-3p in patients with 
glioma. GEO2R was used for the identification of the differen-
tially expressed miRNAs according to the miRNA expression 
profiles obtained from the Gene Expression Omnibus database. 
OncomiR was used to analyze the relationship of miRNAs 
with the survival outcomes of the patients with glioma. A total 
of 108 patients with glioma were recruited to examine the 
expression levels of miR-455-3p and further explore its clinical 
value. The bioinformatics analysis results suggested that a total 
of 64 and 48 differentially expressed miRNAs were identified 
in the GSE90603 and GSE103229 datasets, respectively. There 
were 12 miRNAs in the overlap of the two datasets, of which 
three were able to accurately predict overall cancer survival, 
namely hsa-miR-7-5p, hsa-miR-21-3p and hsa-miR-455-3p. In 
patients with glioma, miR-455-3p was determined to be signif-
icantly upregulated (P<0.001). Additionally, patients with high 
miR‑455‑3p expression had significantly lower 5‑year overall 
survival than those with low miR-455-3p expression (log-rank 
test, P=0.001). Cox regression analysis further determined 
that miR-455-3p was an independent prognostic indicator for 
overall survival in patients with glioma (hazard ratio=2.136; 
95% CI=1.177-3.877; P=0.013). In conclusion, the present study 
revealed a series of miRNAs with potential functional roles in 
the pathogenesis of glioma, and provides findings that indicate 
miR-455-3p as a promising biomarker for the prognosis of 
glioma.
Introduction
Glioma is an aggressive brain cancer with high morbidity and 
mortality rates (1) characterized by aggressive proliferation, 
invasion and dismal prognosis (2). Although great progress has 
been made in the therapeutic field, the prognosis of patients 
with glioma remains poor (3). Recent studies have revealed a 
number of aberrantly expressed genes, which may be involved 
in the progression of glioma (4,5). These findings could provide 
a new perspective for the development of novel therapeutic 
strategies for glioma.
MicroRNAs (miRNAs/miRs) are a class of small 
non-coding RNAs with a length of 20-24 nucleotides (6). 
miRNA dysregulation has been widely reported in numerous 
human diseases, especially cancer (7). miRNAs regulate the 
expression of target messenger RNAs through binding to their 
3'-untranslated region (8). Several miRNAs have been identi-
fied to serve a crucial role in glioma progression and multiple 
cellular processes, including cell proliferation, differentiation, 
apoptosis, migration and invasion. For example, Zhang et al (9) 
indicated that miR-770 expression was markedly lower in 
human glioma tissues and cell lines, and that miR-770 over-
expression suppressed tumor cell proliferation and induced 
apoptosis via targeting CDK8. Lu et al (10) demonstrated that 
the upregulation of miR-6807-3p facilitated carcinogenesis in 
human glioma through promoting cancer cell proliferation and 
migration by targeting dachshund homolog 1. Downregulation 
of miR-139-3p expression was also detected in glioma tissues, 
which may be involved in controlling behaviors associated 
with the malignant progression of glioma, including cell 
proliferation, migration and invasiveness (11). Thus, there 
is a great interest in using aberrantly expressed miRNAs as 
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prognosis prediction markers for glioma. However, it may be 
challenging to detect miRNAs involved in glioma occurrence 
and progression.
In the present study, a number of differentially expressed 
miRNAs in glioma were detected via bioinformatics analysis. 
OncomiR analysis suggested that three miRNAs were able 
to accurately predict overall cancer survival in glioma. The 
differential expression level of miR-455-3p was found to be 
the most significant. Its clinical value has not been investi-
gated. Therefore, miR-455-3p levels were further validated in 
patients with glioma, and its clinical value was explored.
Materials and methods
Microarray data. Firstly, datasets focusing on miRNA 
expression were searched using the following search terms: 
‘Non-coding RNA profiling by array AND glioblastoma’ 
in the National Center for Biotechnology Information Gene 
Expression Omnibus (GEO) database (https://www.ncbi.nlm.
nih.gov/gds/), and only miRNA gene expression profiles were 
included. Additionally, only datasets based on the comparison 
of glioma tissues and healthy samples were included. Datasets 
based on glioma serum, glioma cell lines or animal models 
were excluded. The GSE90603 and GSE103229 (12,13) data-
sets met the inclusion criteria and were subsequently assessed 
using GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r) for 
differential genetic analysis. The combination of the two data-
sets has not been mentioned in previous studies. GSE90603 
contained 16 patients with glioblastoma (GBM) and 7 healthy 
individuals, while GSE103229 contained 5 GBM samples and 
5 normal samples.
Identification of differentially expressed miRNAs. GEO2R 
(http://www.ncbi.nlm.nih.gov/geo/info/geo2r.html) is an 
online tool used to compare two or more groups of samples 
in GEO series for the identification of differentially expressed 
miRNAs under different experimental conditions. In the 
present study, GEO2R was used for the identification of 
differentially expressed miRNAs in glioma, and the adjusted 
P-value <0.05 and |Log fold change (FC)|>2 were chosen as 
cut-off levels.
miRNA expression‑based survival signature analysis. 
OncomiR is able to analyze miRNA-derived survival outcome 
signatures dynamically for one or more types of cancer (14). 
In the present study, the glioma patients were divided into a 
high-risk and low-risk cohort according to the expression 
level of the selected miRNAs, overall cancer survival rates 
were predicted using OncomiR, which was presented with a 
Kaplan-Meier survival curve.
Patients and sample collection. A total of 108 patients with 
primary glioma who underwent primary tumor resection 
between June 2010 and March 2011 at The 900 Hospital of the 
Joint Logistics Team were recruited in the present study. The 
clinicopathological features of glioma patients were collected, 
including age, sex, tumor size, World Health Organization 
(WHO) grade and Karnofsky performance scale (KPS). A 
total of 95 normal brain tissue samples were collected as 
controls from patients who had undergone surgery for cerebral 
injury and cerebral hemorrhage at the same hospital. All tissue 
specimens were immediately snap-frozen in liquid nitrogen 
and stored at ‑80˚C until further processing. No participants 
received radiotherapy or chemotherapy prior to surgery. 
After surgery, all patients were followed up by special clinic 
reexamination, letters or telephones to calculate the 5-year 
survival rate. The interval follow-up time was ~half or one 
year. All procedures were reviewed and approved by the Ethics 
Committee of The 900 Hospital of the Joint Logistics Team. 
Written informed consent was obtained from each participant.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR) of miR‑455‑3p. RT-qPCR was used to determine 
the expression levels of miR-455-3p every two weeks or so 
since the sample collection. Each experiment was repeated 
three times. Total RNA was extracted from glioma and 
normal brain tissues using TRIzol reagent (Thermo Fisher 
Scientific, Inc.), according to the manufacturer's protocol. The 
miScript Reverse Transcription Kit (Qiagen) was used for 
reverse transcription reactions. Next, qPCR was performed 
using the SYBR Green I Master Mix Kit (Invitrogen; Thermo 
Fisher Scientific, Inc.) and the 7300 Real‑Time PCR System 
(Applied Biosystems; Thermo Fisher Scientific, Inc.). The 
primer sequences were as follows: miR-455-3p forward, 
5'-GGG GCA GTC CAT GGG CAT-3' and reverse, 5'-CTC AAC 
TGG TGT CGT GGA-3'; and U6 forward, CTC GCT TCG GCA 
GCA CA and reverse, AAC GCT TCA CGA ATT TGC GT. The 
PCR conditions were as follows: 95˚C for 5 min, followed 
by 40 cycles of 95˚C for 30 sec, 60˚C for 30 sec, and 72˚C 
for 40 sec. Relative miR-455-3p expression was normalized 
to the expression of U6 and was quantified using the 2-ΔΔCq 
method (15).
Statistical analysis. SPSS software (version 18.0; SPSS, 
Inc.) and GraphPad Prism software (version 5.0; GraphPad 
Software, Inc.) were used for data analysis. Measurement 
data between groups were evaluated using the Student's t test, 
whereas counting data were evaluated using the χ2 test. The 
mean expression level of miR-455-3p in glioma tissues was 
used as the cutoff, and the patients were divided into low- and 
high-expression groups. The differences between the two 
groups were compared using the χ2 test. The overall survival 
of patients with glioma was assessed using the Kaplan-Meier 
curve and log-rank test. Cox regression analysis was performed 
to further assess the prognostic value of miR-455-3p in glioma. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Identification of differentially expressed miRNAs. Two 
miRNA expression profiles (GSE90603 and GSE103229) were 
obtained from the GEO database. GSE90603 contained 16 
GBM and 7 normal tissue samples, and GSE103229 contained 
5 GBM and 5 normal tissue samples. A total of 64 differen-
tially expressed miRNAs were identified in the GSE90603 
dataset, and a total of 48 were found in GSE103229. Twelve 
differentially expressed miRNAs were observed to overlap 
between these two datasets (Fig. 1), and the analysis results are 
presented in Table I.
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Kaplan‑Meier survival curves of 12 dif ferentially 
expressed miRNAs. The overall cancer survival was 
predicted using OncomiR, and the results were presented 
with a Kaplan-Meier survival curve. In the present study, 
the glioma patients were divided into high-risk and low-risk 
cohorts according to the expression levels of the selected 
miRNAs. The survival analysis results suggested that only 
three miRNAs reached significant levels among the 12 
differentially expressed miRNAs when predicting overall 
cancer survival, namely hsa-miR-7-5p, hsa-miR-21-3p and 
hsa-miR-455-3p (Fig. 2). The clinical value of miR-455-3p 
in glioma has not been reported in any previous studies and 
its differential expression level was the most significant 
(Table I).
Upregulation of miR‑455‑3p in glioma tissues. The expres-
sion levels of miR-455-3p were examined in 108 glioma 
and 95 normal brain tissue samples. The RT-qPCR results 
suggested that the expression of miR‑455‑3p was significantly 
upregulated in glioma tissues compared with normal tissues 
(P<0.001; Fig. 3).
Association of miR‑455‑3p expression with clinicopathological 
features of patients with glioma. The clinical data of 108 patients 
with glioma are presented in Table II. The mean expression level 
of miR‑455‑3p in glioma tissues was identified as a cut‑off level.
The patients were divided into low (n=44) and high 
miR-455-3p expression (n=64) groups. Differences between 
groups were compared using the χ2 test. It was observed that 
the upregulation of miR-455-3p expression demonstrated 
significant association with high WHO grade (P=0.006) and 
low KPS, P=0.037) in glioma patients. However, miR-455-3p 
expression was not significantly associated with other 
clinicopathological features including age, sex and tumor size 
(all P>0.05; Table II).
Prognostic value of miR‑455‑3p expression in patients with 
glioma. The Kaplan-Meier survival curve and the log-rank 
test were performed to evaluate the association between 
miR‑455‑3p expression and patient survival. It was identified 
that patients with high miR‑455‑3p expression had significantly 
lower 5-year overall survival than those with low miR-455-3p 
expression (log-rank P=0.001; Fig. 4). The multivariate Cox 
regression analysis further suggested that miR-455-3p (hazard 
ratio=2.136; 95% CI=1.177-3.877; P=0.013) was an indepen-
dent prognostic indicator for overall survival in patients with 
glioma (Table III).
Discussion
Glioma is an aggressive central nervous system malignancy, 
which greatly affects human health (16). Owing to rapid prolif-
eration, metastasis and angiogenesis, this disease is relatively 
hard to treat (17,18). The prognosis of patients with glioma is 
relatively poor due to metastasis and recurrence (3,19). The 
incidence and mortality rates of glioma are continuously 
increasing (1). Although numerous epigenetic changes have 
been identified to be associated with glioma, the pathogen-
esis is not fully understood. A recent study reported that a 
number of abnormal miRNAs were found to be involved in 
the transcriptional regulatory network associated with tumor 
initiation and progression (20). Therefore, systematic and inte-
grative analysis is required to explore key miRNAs that may 
contribute to tumor progression.
Currently, microarray and bioinformatics analyses are 
widely used to investigate potential targets for the diagnosis 
and therapy of different types of human cancer (21,22). In the 
present study, a total of 64 differentially expressed miRNAs 
were identified in GSE90603, and 48 were found in GSE103229. 
Among them, 12 differentially expressed miRNAs were 
observed to overlap between these two datasets. OncomiR 
is an online resource for identifying aberrantly expressed 
miRNAs in cancer. In the present study, OncomiR was used to 
examine the predictive value of the differentially expressed 
miRNAs in the overall survival rate of patients with glioma. 
Kaplan-Meier survival curves were generated and the survival 
analysis suggested that only three miRNAs were significantly 
upregulated among the 12 differentially expressed miRNAs, 
namely hsa-miR-7-5p, hsa-miR-21-3p and hsa-miR-455-3p. 
Figure 1. Differentially expressed miRNAs in GSE90603 and GSE103229 
databases. A total of 64 differentially expressed miRNAs were identified in 
GSE90603, while 48 were found in GSE103229. There were 12 overlapping 
differentially expressed miRNAs. miRNAs, microRNAs.
Table I. Twelve differentially expressed miRNAs in the 
overlap of GSE90603 and GSE103229 datasets.
miRNA_ID adj.P.Val Log FC
hsa-miR-455-3p 2.03x10-6 2.30159
hsa-miR-218-5p 1.95x10-4 -2.90172
hsa-miR-7-5p 3.69x10-4 -3.25590
hsa-miR-139-5p 6.13x10-4 -2.88092
hsa-miR-129-1-3p 6.46x10-4 -2.13994
hsa-miR-3200-3p 9.75x10-4 -2.00359
hsa-miR-124-3p 1.43x10-3 -4.08201
hsa-miR-129-5p 2.31x10-3 -2.68730
hsa-miR-21-3p 3.74x10-3 2.308139
hsa-miR-338-5p 4.85x10-3 -2.08672
hsa-miR-138-5p 6.96x10-3 -3.01343
hsa-miR-491-5p 9.93x10-3 -2.03053
miRNA, microRNA; adj.P.Val, adjusted P-value; FC, fold change.
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All results indicated the potential involvement of miR-7-5p, 
miR-21-3p and miR-455-3p in glioma. Regarding miR-7-5p, 
Liu et al (23) have reported its downregulation in GBM 
microvessels compared with normal brain capillaries. In the 
same study, it was demonstrated that miR-7-5p may function 
as a tumor suppressor by inhibiting vascular endothelial cell 
proliferation through Raf1 targeting. Furthermore, different 
expression of miR-7-5p has been detected in other types of 
human cancer, including bladder cancer, breast cancer and 
melanoma (24‑26). These findings indicate the crucial role 
of miR-7-5p in cancer development. miR-21-3p, the passenger 
strand of pre-miR-21, has been widely reported to be aberrantly 
expressed in various types of human cancer. Tseng et al (27) 
suggested that miR‑21‑3p expression is significantly upregu-
lated in oral squamous cell carcinoma tissues compared with 
corresponding adjacent normal tissues. In glioma, miR-21-3p 
was proven to regulate glioma cell proliferation and apoptosis 
by downregulating the expression of PTEN protein (28).
Regarding miR-455-3p, it has been reported to serve a 
role in acquired temozolomide resistance in patients with 
glioma (29-31). A recent study suggested that miR-455-3p was 
significantly increased in glioma cell lines and may regulate 
tumor cell progression (32). However, its expression levels and 
clinical significance have not been assessed in patients with 
glioma. In the present study, the bioinformatics analysis results 
suggested that the differential expression level of miR-455-3p 
in glioma was the most significant. Subsequently, its expres-
sion in patients with glioma was examined. Consistent with 
the bioinformatics analysis results, the expression levels of 
miR‑455‑3p were significantly upregulated in glioma tissues 
compared with normal tissues. Based on malignancy degree, 
WHO has divided gliomas into four grades: i) Pilocytic 
astrocytoma (WHO grade I), ii) diffuse astrocytoma (WHO 
Figure 3. Expression levels of miR-455-3p measured by RT-qPCR in 
glioma and normal brain tissues. miR‑455‑3p expression was significantly 
upregulated in the glioma tissues compared with the normal brain tissues. 
***P<0.001. RT-qPCR, reverse transcription-quantitative polymerase chain 
reaction; miR, microRNA.
Figure 2. Survival analysis of the 12 identified differentially expressed miRNAs. The glioma patients were divided into high‑risk cohort low‑risk groups 
according to the miRNA expression levels. OncomiR was used to examine the significance of the observed differentially expressed miRNAs in predicting 
overall cancer survival, and only three miRNAs were significantly upregulated among the 12 differentially expressed miRNAs, namely hsa‑miR‑7‑5p, 
hsa-miR-21-3p and hsa-miR-455-3p (P<0.05). miRNAs/miRs, microRNAs.
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grade II), iii) anaplastic astrocytoma (WHO grade III); and 
iv) GBM multiform (WHO grade IV) (33). In the present 
study, the histopathological WHO grades and KPS score, 
which are currently used to predict prognosis in patients 
with glioma, were recorded (34). It was observed that the 
upregulation of miR-455-3p was closely associated with high 
WHO grade and low KPS score, indicating the potential 
prognostic value of miR-455-3p in glioma. As suggested 
by the bioinformatics analysis, miR-455-3p may be used 
as a potential prognostic marker in glioma. Moreover, the 
Kaplan-Meier survival curves and log-rank test were also 
performed, and it was confirmed that miR‑455‑3p served as 
an independent prognostic indicator for overall survival and 
that high miR-455-3p expression levels were associated with 
poor prognosis. The abnormal expression of miR-455-3p and 
its prognostic value have been widely reported in numerous 
types of human cancer (35-37). For example, Gao et al (37) 
reported that miR‑455‑3p was significantly downregulated in 
non-small cell lung cancer, while low miR-455-3p expression 
was an unfavorable prognostic factor for overall survival. 
Another study suggested that miR-455-3p functioned as a 
tumor suppressor in esophageal squamous cell carcinoma 
(ESCC) and inhibited cell proliferation and invasion by 
targeting FAM83F. In addition, low miR-455-3p expression 
was identified as an unfavorable prognostic factor for the 
overall survival of patients with ESCC (38). Nevertheless, the 
functional role and underlying mechanism of miR-455-3p in 
glioma was not examined in the present study, thus further 
studies are required. Additionally, certain limitations are 
included in the present study. Firstly, it is generally accepted 
that higher tumor grade is associated with poorer prognosis, 
however KPS revealed no significant association with the 
prognosis of patients with glioma, although results indicated 
that the difference was close to statistical significance. This 
may be due to the sample size being relatively small; a larger 
study would be required to confirm the present results of 
the present study. Secondly, according to the bioinformatics 
analysis, several differentially expressed miRNAs were iden-
tified to be associated with glioma prognosis, though only 
one major miRNA was investigated. Additional miRNAs 
may be investigated in future studies. Lastly, the clinical and 
pathological information included in the present study were 
limited. For example, although the mutation status of isocitrate 
dehydrogenase 1 and 1p19q, which may serve an important 
role in the prognosis of patients with glioma, have attracted 
broad attention during the last decades (32,39); these were not 
examined in the present study. In future studies, these clinical 
and pathological parameters should be included.
Table II. Association of miR-455-3p with the clinicopatho-
logical features of patients with glioma.
 miR-455-3p expression
 --------------------------------------------------
Feature n=108 Low (n=44) High (n=64) P-value
Age (years)    0.383
  ≤60 51 23 28 
  >60 57 21 36 
Sex    0.942
  Male 56 23 33 
  Female 52 21 31 
Tumor size (cm)    0.354
  ≥5.0 67 25 42 
  <5.0 41 19 22 
WHO grade    0.006a
  I-II 64 33 31 
  III-IV 44 11 33 
KPS    0.037b
  <80 62 20 42 
  ≥80 46 24 22
aP<0.01. bP<0.05. WHO, World Health Organization; KPS, Karnofsky 
performance scale.
Table III. Multivariate Cox regression analysis for miR-455-3p 
in patients with glioma.
 Multivariate analysis
 -------------------------------------------------
Variable HR 95% CI P-value
miR-455-3p 2.136 1.177-3.877 0.013a
Age 0.899 0.551-1.468 0.671
Sex 1.115 0.693-1.793 0.654
Tumor size 0.808 0.490-1.332 0.403
WHO grade 1.607 0.973-2.654 0.064
KPS 0.789 0.472-1.319 0.367
aP<0.05. miR, microRNA; HR, hazard ratio; CI, confidence interval; 
WHO, World Health Organization; KPS, Karnofsky performance 
scale.
Figure 4. Kaplan-Meier survival analysis for the patients with glioma based 
on the expression of miR-455-3p. Patients with high miR-455-3p expres-
sion had shorter survival time than those with low miR-455-3p expression 
(log-rank P=0.001). miR, microRNA.
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In conclusion, 12 differentially expressed miRNAs were 
identified via integrative analysis of GEO data and OncomiR 
analysis suggested that among them, three miRNAs were 
able to accurately predict overall cancer survival in glioma. 
Furthermore, miR-455-3p upregulation was validated in 
patients with glioma, and it was indicated as a potential 
prognostic biomarker for glioma. The present study identi-
fied a series of miRNAs with potential functional roles in 
the pathogenesis of glioma, and provides evidence for the 
use of miR-455-3p as a promising biomarker for glioma 
prognosis.
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